FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Bristol Myers Squibb.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Multiple Myeloma
- Sub-indication
- General
Related signal: Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy